Bank of Montreal Can trimmed its stake in shares of Sanofi SA (NYSE:SNY) by 8.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,703 shares of the company’s stock after selling 4,033 shares during the quarter. Bank of Montreal Can’s holdings in Sanofi were worth $1,862,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Squar Milner Financial Services LLC bought a new stake in shares of Sanofi during the 2nd quarter worth about $169,000. New England Research & Management Inc. bought a new stake in shares of Sanofi during the 3rd quarter worth about $205,000. Natixis bought a new stake in shares of Sanofi during the 2nd quarter worth about $213,000. We Are One Seven LLC bought a new stake in shares of Sanofi during the 3rd quarter worth about $227,000. Finally, Huntington National Bank raised its position in shares of Sanofi by 24.9% during the 2nd quarter. Huntington National Bank now owns 6,037 shares of the company’s stock worth $242,000 after buying an additional 1,202 shares in the last quarter. Institutional investors own 7.53% of the company’s stock.
A number of analysts have commented on the stock. Argus boosted their price target on shares of Sanofi from $48.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Thursday, November 1st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Wednesday, October 31st. Wolfe Research assumed coverage on shares of Sanofi in a research note on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Finally, ValuEngine raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $49.50.
Shares of SNY opened at $45.59 on Friday. The company has a market capitalization of $111.91 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 2.53 and a beta of 0.70. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a 12-month low of $37.43 and a 12-month high of $46.25.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.09. The company had revenue of $9.39 billion for the quarter, compared to analysts’ expectations of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS. As a group, research analysts forecast that Sanofi SA will post 3.09 EPS for the current fiscal year.
In other news, major shareholder Sanofi sold 104,552 shares of Sanofi stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.00% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Story: Retained Earnings
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.